open-label BE trials maintain blindness [Study Per­for­mance]

posted by kimhuang – China, 2023-10-14 11:19 (600 d 16:23 ago) – Posting: # 23752
Views: 5,431

How do open-label BE trials maintain blindness until the database is locked?
Holding a data review meeting before DBL to discuss whether PK parameters (such as Pre-dose concentration, Abnormal PK concentration profiles, λz estimation, %AUCextrap etc.) are included in the analysis set (without treatment assigment) will have risk of potential unblinding?


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
20 visitors (0 registered, 20 guests [including 15 identified bots]).
Forum time: 03:43 CEST (Europe/Vienna)

No computer has ever been designed
that is ever aware of what it’s doing;
but most of the time, we aren’t either.    Marvin Minsky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5